{"created":"2023-07-27T06:29:19.580506+00:00","id":14091,"links":{},"metadata":{"_buckets":{"deposit":"a4e15d1b-7e40-4eeb-9f96-7f72fdbc6da8"},"_deposit":{"created_by":3,"id":"14091","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14091"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014091","sets":["4168:4173:4174"]},"author_link":["22727","1202","1004","93","2534","78612","2822","62","660","339","76701","21570","24029","23243"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-11-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"12","bibliographicPageEnd":"1185","bibliographicPageStart":"1179","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"Hepatology Research"}]}]},"item_4_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"寺島, 健志"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"山下, 竜也"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"荒井, 邦明"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"砂子坂, 肇"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"北原, 征明"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"加賀谷, 尚史"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"水腰, 英四郎"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"本多, 政夫"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"金子, 周一"}],"nameIdentifiers":[{},{},{},{}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aim: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, although there is no proven therapeutic procedure following the termination of sorafenib, hepatic arterial infusion chemotherapy (HAIC) may be a treatment option in advanced HCC. The aim of this study was to evaluate feasibility and efficacy of HAIC for patients with advanced HCC as subsequent therapy. Methods: We retrospectively evaluated 27 consecutive patients with advanced HCC who were treated with HAIC following sorafenib between June 2009 and December 2012 at our hospital. Cisplatin (20 mg/m2 per day) was administered via the hepatic artery for 10 min, prior to the continuous administration of 5-fluorouracil (330 mg/m2 per day) over 24 h from days 1-5 and 8-12 and the s.c. administration of pegylated interferon α-2b (1 μg/kg) on days 1, 8, 15, and 22. A treatment cycle consisted of 28 days of drug administration followed by 14 days of rest. Results: The toxicity profile showed that hematological toxicities were common, and grade 3/4 neutropenia and thrombocytopenia were observed (51.9% and 48.1%, respectively). Five patients (18.5%) experienced device-related complications. No unexpected adverse reactions and no treatmentrelated deaths were observed. Partial response was obtained in eight patients (29.6%), and stable disease was noted in nine patients (33.3%). Median progression-free survival and median survival time from initiation of HAIC were 4.0 and 7.6 months, respectively. Conclusions: Because HAIC was well tolerated and exhibited moderate antitumor activity, it is a potentially useful treatment procedure in patients with advanced HCC even after failure of sorafenib.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_4_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00014078","subitem_identifier_reg_type":"JaLC"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Blackwell Publishing / 日本肝臓学会 Japan Society of Hepatology"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/hepr.12266","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA11140867","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1386-6346","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Terashima, Takeshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Yamashita, Tatsuya"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Arai, Kuniaki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Sunagozaka, Hajime"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Kitahara, Masaaki"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Nakagawa, Hidetoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kagaya, Takashi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Mizukoshi, Eishiro"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Honda, Masao"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Kaneko, Shuichi"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-KANEKO-S-1179.pdf","filesize":[{"value":"319.9 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-KANEKO-S-1179.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14091/files/ME-PR-KANEKO-S-1179.pdf"},"version_id":"15183e44-1f74-48c7-b0aa-59e1d71f1900"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib"}]},"item_type_id":"4","owner":"3","path":["4174"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14091","relation_version_is_last":true,"title":["Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T10:17:16.528080+00:00"}